Astrazeneca Plc
- All
- News
- Videos
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
Enhertu Sharply Improves Survival In Breast Cancer Patients: Report
A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.
-
AstraZeneca Booster Significantly Boosts Antibodies Against Omicron
A third dose of AstraZeneca Plc's Covid-19 vaccine significantly boosted neutralizing antibody levels against Omicron, according to lab studies at the University of Oxford.
-
Omicron vs Vaccines Shows What Scientists Fear In New Study
The omicron variant dented the protection afforded by two doses of Pfizer Inc.'s and AstraZeneca Plc's Covid vaccines as feared, researchers found, increasing the risk of infection.
-
Mixing Covid Vaccines Is Effective In Study on Pfizer, AstraZeneca
Mixing other vaccines with those from AstraZeneca Plc or Pfizer Inc. offers at least as effective protection against Covid-19 as giving two doses of the same shots, a UK study found.
-
Possible New Links Between AstraZeneca Vaccine And Blood Clots
Scientists have identified a possible reason the AstraZeneca Plc Covid-19 vaccine may cause blood clots, after use of the shot was limited globally to prevent the rare side effect.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
Blood Clot Risk Much Higher From Covid Than With Vaccines: UK Study
Covid-19 patients face a much higher risk of developing blood clots than those vaccinated with AstraZeneca Plc or Pfizer Inc.'s shots, according to a large U.K. study.
-
AstraZeneca Says Its Antibody Cocktail Prevents Covid In High-Risk Groups
AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
EU Should OK Covishield In A Month, Says Maker Adar Poonawalla
The Serum Institute of India expects European drug regulators will approve Covishield -- the Covid-19 shot it manufactures in partnership with AstraZeneca Plc -- in a few weeks, paving way for it to be added to the region's 'Green Pass' list.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
AstraZeneca Says Its Vaccine Effective Against Variants Identified In India
AstraZeneca Plc's COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study.
-
AstraZeneca's Antibody Cocktail Fails to Prevent Covid: Study
AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.
-
2 AstraZeneca Doses Give Up to 90% Protection From Covid Symptoms: UK
Two doses of AstraZeneca Plc's Covid-19 vaccine provide about 85% to 90% protection against symptomatic disease, according to statistics released by Public Health England on Thursday.
-
AstraZeneca Nasal Spray Vaccine For Covid Fizzles In Small, Early Trial
AstraZeneca Plc's ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
-
Enhertu Sharply Improves Survival In Breast Cancer Patients: Report
A drug from AstraZeneca Plc and Daiichi Sankyo Co. extended the lives of patients with an advanced form of breast cancer by about six months in a late-stage trial that may widen the population of people who can benefit from the treatment.
-
AstraZeneca Booster Significantly Boosts Antibodies Against Omicron
A third dose of AstraZeneca Plc's Covid-19 vaccine significantly boosted neutralizing antibody levels against Omicron, according to lab studies at the University of Oxford.
-
Omicron vs Vaccines Shows What Scientists Fear In New Study
The omicron variant dented the protection afforded by two doses of Pfizer Inc.'s and AstraZeneca Plc's Covid vaccines as feared, researchers found, increasing the risk of infection.
-
Mixing Covid Vaccines Is Effective In Study on Pfizer, AstraZeneca
Mixing other vaccines with those from AstraZeneca Plc or Pfizer Inc. offers at least as effective protection against Covid-19 as giving two doses of the same shots, a UK study found.
-
Possible New Links Between AstraZeneca Vaccine And Blood Clots
Scientists have identified a possible reason the AstraZeneca Plc Covid-19 vaccine may cause blood clots, after use of the shot was limited globally to prevent the rare side effect.
-
Covishield, China's Sinovac Approved By Australia Ahead Of Border Opening
Australia recognized China's Sinovac Biotech Ltd. COVID-19 shot and India-made AstraZeneca Plc jabs, paving the way for overseas travelers and fee-paying foreign students who have received those vaccinations to enter the country.
-
Blood Clot Risk Much Higher From Covid Than With Vaccines: UK Study
Covid-19 patients face a much higher risk of developing blood clots than those vaccinated with AstraZeneca Plc or Pfizer Inc.'s shots, according to a large U.K. study.
-
AstraZeneca Says Its Antibody Cocktail Prevents Covid In High-Risk Groups
AstraZeneca Plc's Covid-19 antibody cocktail was found to be 77% effective in preventing symptomatic Covid-19 in high-risk people in a key trial that could expand the range of drugs available to vulnerable groups.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
EU Should OK Covishield In A Month, Says Maker Adar Poonawalla
The Serum Institute of India expects European drug regulators will approve Covishield -- the Covid-19 shot it manufactures in partnership with AstraZeneca Plc -- in a few weeks, paving way for it to be added to the region's 'Green Pass' list.
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
AstraZeneca Says Its Vaccine Effective Against Variants Identified In India
AstraZeneca Plc's COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study.
-
AstraZeneca's Antibody Cocktail Fails to Prevent Covid: Study
AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.
-
2 AstraZeneca Doses Give Up to 90% Protection From Covid Symptoms: UK
Two doses of AstraZeneca Plc's Covid-19 vaccine provide about 85% to 90% protection against symptomatic disease, according to statistics released by Public Health England on Thursday.
